Cancer & Oncology Clinical Trials Update: Week 16, 2026

Published April 17, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

This Phase 3 study is exploring the use of tarlatamab, a new treatment option for patients with limited-stage small cell lung cancer who have completed chemoradiotherapy and have not seen their cancer progress. If successful, this therapy could help improve survival rates for this aggressive form of lung cancer. The trial is currently recruiting patients in several countries, offering hope for a broader treatment choice in the future.

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

This Phase 3 trial is testing gotistobart, a new antibody treatment, against standard chemotherapy for patients with metastatic non-small cell lung cancer that has worsened after immunotherapy. A positive outcome could provide an important new option for patients whose cancer no longer responds to current immune-based treatments. The trial is recruiting participants globally and involves receiving infusions every three weeks for up to a year.

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

This Phase 3 trial evaluated elinzanetant, a new oral medication designed to reduce hot flashes caused by hormone therapy in women with hormone-receptor positive breast cancer or those at high risk of developing it. Managing hot flashes effectively can greatly improve quality of life and help women stay on their cancer treatments. The study is complete with results available from multiple countries, contributing valuable information on supportive care during cancer treatment.

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

This Phase 3 trial in China is testing an innovative approach where artificial intelligence helps guide targeted therapy for patients with early or locally advanced HER2-positive breast cancer before surgery. This personalized treatment strategy aims to improve outcomes by better matching therapies to each patient’s cancer characteristics. Recruiting is ongoing, and the results may shape future treatment plans for this type of breast cancer.

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

This Phase 3 trial is comparing taletrectinib, an oral targeted therapy, with the current standard treatment crizotinib in patients with ROS1-positive non-small cell lung cancer who have not yet received ROS1-targeted therapy. Success in this study could provide a new effective treatment option to better control disease in this patient group. The study is recruiting in China and plans to enroll nearly 200 participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.